274 Novel cysteine derivatives for the next generation anticancer agents acting on KSP

physical properties for oral administration. AZD8186 showed profound pharmacodynamic modulation of p-Akt in PTEN-null PC3 prostate tumour bearing mice after oral administration and showed complete inhibition of tumour growth in the mouse PTEN-deficient PC3 prostate tumour xenograft model. AZD8186 was selected as a clinical candidate for treatment of PTEN-dependent cancers and has recently entered phase I clinical trials.